Dr. Kristy M. Ainslie's lab focuses on innovative therapies for challenging medical conditions such as glioblastoma and autoimmune diseases. By using biomaterials, particularly specialized biodegradable polymers, the lab aims to improve the effectiveness of immune cell therapies and develop new strategies for inducing immune tolerance. The research integrates advanced materials with cell therapy to enhance patient outcomes and advance the field of immunotherapy.

Dr. Konstantin Popov's lab at the University of North Carolina Chapel Hill focuses on developing new drug discovery methods to tackle Alzheimer's disease using artificial intelligence. The lab integrates computational techniques with experimental workflows to identify and optimize small-molecule drugs that can influence key proteins involved in the disease. By combining modern technology with traditional research methods, the lab aims to create effective therapies for neurodegenerative disorders.

Professor Joseph Mauro Calabrese's research focuses on understanding the mechanisms of long noncoding RNAs (lncRNAs) in gene regulation. These specialized RNA molecules, which do not code for proteins, play important roles in silencing genes that can affect health and disease, including conditions like Angelman and Rett Syndromes. The lab aims to uncover how these lncRNAs work at the molecular level and how their functions can lead to potential therapeutic discoveries.

Dr. Michael Emanuele's lab at the University of North Carolina Chapel Hill focuses on understanding how proteins regulate the cell cycle, particularly through a process called ubiquitination, which involves tagging proteins for degradation. His research examines the specific enzymes and proteins involved in this tagging process and their effects on cell growth and division. This work is crucial for uncovering how misregulation of these processes can lead to diseases like cancer.

Dr. David S. Lawrence's lab at the University of North Carolina Chapel Hill focuses on developing innovative drug delivery systems to improve treatments for thromboembolism, particularly in cancer patients. The lab's groundbreaking research utilizes a bioengineering approach that combines thrombolytic enzymes with vitamin B12 to create a targeted, effective delivery platform, using the body's circulatory system as a natural reservoir. This technology aims to enhance the safety and efficacy of thrombolytic therapies, especially in high-risk populations like cancer patients and pregnant women.

Dr. Henrik G. Dohlman's lab at the University of North Carolina Chapel Hill focuses on the intricacies of cell signaling mediated by G protein-coupled receptors. The lab's research aims to uncover the unique behaviors of different G protein subtypes and how they interact with hormones, neurotransmitters, and drugs. Their work is significant for understanding human diseases and could lead to the development of better pharmaceutical treatments.

Dr. Paul B. Watkins' lab at the University of North Carolina Chapel Hill focuses on understanding how genetic differences influence the effectiveness and safety of adeno-associated virus (AAV) gene therapies, particularly related to liver toxicity. By studying a diverse population of genetically different mice, the lab aims to uncover the underlying genetic factors that contribute to variability in how patients respond to AAV treatments. This research is intended to improve the design of safer and more effective gene therapies for genetic disorders that require liver targeting.

Dr. Klaus M. Hahn's lab focuses on understanding how cells communicate and behave by developing advanced imaging techniques to visualize and control protein activity in real time. They study the dynamics of signaling in various contexts, like immune cells and cancer progression, to uncover fundamental principles of cell biology. The aim is to create tools that can help researchers explore diverse biological questions, especially related to how cells react to their environment.

Dr. Samuel Lai's lab at the University of North Carolina focuses on developing innovative therapies for respiratory infections caused by viruses like parainfluenza and metapneumovirus. The lab is working on engineering antibodies that can trap these viruses in airway mucus, potentially offering new treatment options for children and immunocompromised adults who are vulnerable to severe respiratory illnesses. The research aims to enhance how antibodies work at mucosal surfaces to combat respiratory infections.

Dr. Juan Song's lab at the University of North Carolina Chapel Hill focuses on understanding how certain brain regions regulate the creation of new neurons, which is important for memory and emotional processing. By studying cells in the hypothalamus, they aim to enhance the growth of neurons to improve brain function, especially in conditions like Alzheimer's disease. This research has the potential to lead to new therapies for treating cognitive and emotional disorders.

Dr. Juliane Nguyen's research lab focuses on developing innovative therapies using engineered probiotics and extracellular vesicles to improve treatments for chronic diseases like inflammatory bowel disease and ischemic heart disease. The lab aims to create safer, more effective medicine that targets the root causes of these conditions, potentially enhancing patient recovery and quality of life. By integrating advanced technologies in pharmacology and biomedical engineering, Dr. Nguyen's team seeks to bridge the gap between laboratory research and clinical application.

Dr. Elias Rosen's lab at the University of North Carolina Chapel Hill focuses on understanding how antiretroviral drugs penetrate tissues during HIV treatment. By using advanced imaging techniques, the lab investigates how the structure of tissues may affect drug delivery and how this impacts the efficacy of HIV therapies. The goal is to optimize treatment strategies to improve clinical outcomes for individuals with HIV.

Dr. Bryan L. Roth's lab focuses on understanding how psychoactive drugs, like LSD, interact with specific receptors in the brain that are crucial for treating mental disorders. They use advanced techniques to study the structures of serotonin and Mas-related receptors to uncover how these drugs work at a molecular level. This research aims to improve drug design for conditions such as schizophrenia and chronic pain, leading to safer and more effective treatments.